Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression

This is the authors' abstract. We don't add key points for this paper.

In seven major kidney clinical trials, the WO and HR provided similar direction of treatment effect estimates with smaller HRs associated with larger WOs. The prioritization of clinical outcomes and inclusion of broader composite end points makes the HCE an attractive alternative to the established kidney end point.